Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Sionna Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$35.92

-0.13 (-0.36%)

C 40Pipeline Score Overvalued Biotech · Commercial
Market Cap
1.86 B
EPS
-1.92
P/E Ratio
-
Value Trade
11.75 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • R&D Expenses

    18.96 M

  • Operating CF

    -21.84 M

  • Total Assets

    305.04 M

  • Total Liabilities

    16.83 M

  • Equity

    288.21 M

  • D/E Ratio

    12,345

-1.77 %
Week
-1.63 %
1 Month
10.8 %
3 Month
6.33 %
6 Month
64.52 %
5 Year
64.52 %
All Time
Cash Data
Healthy

  • Cash Position

    289.93 M

  • Monthly Burn

    7.28 M

  • Runway

    38.8 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 12, 2026
Overview
Volume
189.64 K
52 Week Range
12.53 - 48.45
% held by Insiders
41.65 %
% held by Institutions
63.09 %
Enterprise Value
1.65 B
Total Shares
44.73 M
Short %
56.07 %
Float Shares
8.27 M
Company Description
HQ: 21 HICKORY DRIVE, SUITE 500, W...
Employees:59
https://www.sionnatx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
phase 2a data readout example
SION-719 Cystic Fibrosis
Phase 2a
—
Small Molecules
Respiratory System
SION-719 Cystic Fibrosis
Phase 2a
—
Small Molecules
Respiratory System
SION-719 Cystic Fibrosis
Phase 2a
—
Small Molecules
Respiratory System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C40
Pipeline Score
$231M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.4x
rNPV / MCap
Top 53%
Micro Cap
(rank 426 of 905)
Percentile Rank
Sionna Therapeutics, Inc. carries a moderate pipeline score (40/100), with $578M risk-adjusted pipeline value, led by SION-719 in Cystic Fibrosis (CF) (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
SION-719
Small molecule		Cystic Fibrosis (CF)Phase 2NCT0710815314% $402M ACTIVE NOT_RECRUITING 16 AVERAGE B (63) Jul 1, 2026ELEVATED_RISKMEDIUM
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
SION-719, SION-451
cystic fibrosis
Phase 1
2025-08-12
SION-719, SION-451
cystic fibrosis
Phase 1
2025-08-12
SION-719, SION-451
cystic fibrosis
Phase 1
2025-08-12
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in SION
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Sionna Therapeutics, Inc. (SION) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
SION
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SION
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SION
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
SION Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
SION Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Sionna Therapeutics, Inc. (SION) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How SION ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Cystic Fibrosis #2 of 7 PHASE 2 SION-719
VRTX PHGE FDMT
$13.49B 0.9 CONTENDER